Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
New Strong Buy Stocks for February 29th
07:51am, Thursday, 29'th Feb 2024
UGP, KNSA, EIG, AMSF and HMC have been added to the Zacks Rank #1 (Strong Buy) List on February 29, 2023.
Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript
11:58am, Wednesday, 28'th Feb 2024
Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Wednesday, 28'th Feb 2024
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
09:40am, Wednesday, 28'th Feb 2024
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
07:30am, Wednesday, 28'th Feb 2024
– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
04:01pm, Wednesday, 21'st Feb 2024
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 a
Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know
10:56am, Monday, 12'th Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is qu
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Monday, 12'th Feb 2024
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
How Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93%
10:56am, Tuesday, 23'rd Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 43.9% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is qu
Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why
09:51am, Tuesday, 23'rd Jan 2024
Kiniksa Pharmaceuticals, Ltd. (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Is Kiniksa Pharmaceuticals (KNSA) Stock a Solid Choice Right Now?
10:31am, Tuesday, 09'th Jan 2024
Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag
04:29pm, Friday, 05'th Jan 2024
Kiniksa Pharmaceuticals, Ltd.'s phase 2 results for KPL-404 in rheumatoid arthritis were unimpressive, and the company should quickly switch focus to other indications. The commercial uptake of Arcaly
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 02'nd Jan 2024
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday,
The 3 Most Undervalued Biotech Stocks to Buy in December
02:30pm, Friday, 15'th Dec 2023
As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company's making these strides have incredible results to show for it.
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
03:47pm, Friday, 24'th Nov 2023
Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.
